Lantern Pharma (LTRN) Retained Earnings (2019 - 2026)
Lantern Pharma's (LTRN) quarterly Retained Earnings came in at -$35637.0 in Q1 2026, up 99.96% YoY from -$17822.4 in Q1 2025, and up 99.96% on a QoQ basis from -$93.1 million in Q4 2025.
Lantern Pharma (LTRN) Retained Earnings (2019 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 8 years of Retained Earnings data on file, last reported at -$35637.0 in Q1 2026.
- Quarterly Retained Earnings rose 99.96% year-over-year to -$35637.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$35637.0 (up 99.96% YoY) and the FY2025 annual result came in at -$93.1 million, down 22.52% from the prior year.
- Retained Earnings improved to -$35637.0 in Q1 2026, from -$93.1 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $97.4 million in Q2 2025 to a low of -$93.1 million in Q4 2025.
- A 5-year average of -$5.9 million and a median of -$371386.0 in 2022 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 323.51% in 2024, down 50443.56% in 2024.
- Tracing LTRN's Retained Earnings over 5 years: stood at -$371386.0 in 2022, then plunged by 14775.2% to -$55.2 million in 2023, then sank by 37.62% to -$76.0 million in 2024, then slipped by 22.52% to -$93.1 million in 2025, then soared by 99.96% to -$35637.0 in 2026.
- The last three Retained Earnings figures came in at -$35637.0 (Q1 2026), -$93.1 million (Q4 2025), and $40333.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Lantern Pharma | 26.11 Mn | 26.11 Mn | - | 99.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35,637.00 |
| Dec 31, 2025 | -93.15 Mn |
| Sep 30, 2025 | 40,333.00 |
| Jun 30, 2025 | 97.37 Mn |
| Mar 31, 2025 | -80.56 Mn |
| Dec 31, 2024 | -76.03 Mn |
| Sep 30, 2024 | -70.15 Mn |
| Jun 30, 2024 | -65.64 Mn |
| Mar 31, 2024 | 96.45 Mn |
| Dec 31, 2023 | -55.24 Mn |
| Sep 30, 2023 | -138,792.00 |
| Jun 30, 2023 | 96.42 Mn |
| Mar 31, 2023 | -43.15 Mn |
| Dec 31, 2022 | -371,386.00 |
| Sep 30, 2022 | -435,035.00 |
| Jun 30, 2022 | 95.06 Mn |
| Mar 31, 2022 | -311,469.00 |
| Dec 31, 2021 | -92,689.00 |
| Sep 30, 2021 | 97.31 Mn |
| Jun 30, 2021 | 97.09 Mn |